Overall Status

Active, not recruiting (1)

Completed (1)

Not yet recruiting (1)

Withdrawn (1)

Phase

n/a (2)

phase 2 (2)

Sponsor

Activ Surgical (1)

International Agency for Research on Cancer (1)

Jules Bordet Institute (1)

Qilu Hospital of Shandong University (1)

Collaborator

Eli Lilly and Company (1)

Kilimanjaro Clinical Research Institute (1)

University of Cambridge (1)

University of Pittsburgh Medical Center (1)

Intervention

abemaciclib (1)

activsight (1)

cytosponge™ (1)

paclitaxel and cisplatin (1)

sintilimab injection plus paclitaxel and cisplatin (1)

Study Documents

Intervention Type

device (2)

drug (2)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (4)

esophagus scc

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Esophagus Cancer, Esophageal Cancer, Esophageal Tumors Trial in Pittsburgh (ActivSight)

Not yet recruiting

Esophagus Cancer
+9 more

ActivSight

Pittsburgh, Pennsylvania

University of Pittsburgh Medical Center - Dept of Cardiothoracic

Jan 31, 2023

Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma Trial in Belgium, France (Abemaciclib)

Active, not recruiting

Esophageal Adenocarcinoma
+4 more

Abemaciclib

Antwerpen, Belgium
+10 more

May 27, 2022

Esophagus SCC Trial in Jinan (Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin)

Withdrawn

Esophagus SCC

Sintilimab Injection plus Paclitaxel and Cisplatin
Paclitaxel and Cisplatin

Jinan, Shandong, China

Qilu Hospital of Shandong University

Apr 19, 2022

Esophageal Diseases, Esophagus SCC Trial in Moshi (Cytosponge™)

Completed

Esophageal Diseases
Esophagus SCC

Cytosponge™

Moshi, Tanzania

Majengo Unit, Kilimanjaro Clinical Research Institute

Aug 24, 2021